Melatonin

Melatonin operates through at least four distinct mechanistic pathways that together account for its diverse physiological effects: (1) MT1/MT2 receptor activation for circadian and sleep effects; (2) nuclear receptor (ROR/RZR) modulation for anti-inflammatory and metabolic effects; (3) direct and indirect antioxidant activity particularly in mitochondria; (4) modulation of calcium signaling, calmodulin binding, and membrane fluidity in neuronal tissues.

MT1 and MT2 receptors are seven-transmembrane G-protein-coupled receptors (GPCRs) of the superfamily that includes serotonin, dopamine, and adrenergic receptors. MT1 is most highly expressed in the suprachiasmatic nucleus (SCN) of the hypothalamus — the master circadian pacemaker — where melatonin binding reduces SCN neuronal firing, promotes sleep propensity, and generates the subjective experience of nighttime. MT2 is expressed in the SCN as well as the hippocampus, retina, and blood vessels; MT2 signaling is primarily responsible for circadian phase shifts (the chronobiotic effect) rather than acute sleep induction. The clinical implication of this dual-receptor system is that acute evening melatonin activates MT1 to promote sleep initiation and MT2 to advance circadian phase (shifting the entire circadian system earlier) — making melatonin useful for both immediate sleep and for correcting late-chronotype circadian disorders. The dual-agonist profile distinguishes melatonin from selective MT1 or MT2 agonists in pharmaceutical development and from sedatives that only induce acute sleep without circadian effects.

Both receptors signal through Gi coupling (inhibiting adenylyl cyclase and reducing cAMP) and through Gq (activating phospholipase C and increasing intracellular calcium transients). MT1 activation in the SCN reduces firing rates of pacemaker neurons via potassium channel opening and calcium channel closing. MT2 activation in the SCN produces phase shifts through transcriptional regulation of the core clock genes PER, CRY, BMAL1, and CLOCK. Receptor density is subject to homologous desensitization (chronic high-dose melatonin downregulates MT1/MT2 surface expression over weeks, reducing effectiveness) — this is the mechanistic basis for the clinical observation that lower doses and intermittent dosing are often more effective than high doses daily, and why many practitioners recommend 2-3 nights off per week or cycling melatonin-free weeks.

Ramelteon (Rozerem, FDA-approved 2005) is a selective MT1/MT2 agonist ~6-fold more potent than melatonin at MT1 and 3-fold more potent at MT2, without activity at other receptors; tasimelteon (Hetlioz, FDA-approved 2014) is similarly selective and indicated for non-24-hour sleep-wake disorder in blind individuals; agomelatine is a European-approved melatonin agonist + 5-HT2C antagonist used as an antidepressant. The existence of these synthetic agonists validates the MT1/MT2 pathway as the primary sleep-relevant target, while also revealing that melatonin's broader effects (antioxidant, immunomodulatory, oncostatic) depend on non-receptor and nuclear-receptor mechanisms not replicated by the selective GPCR agonists.

Nuclear receptor (RORα/RZRα, RORβ) binding provides a second mechanistic axis. Melatonin directly binds these retinoid-related orphan nuclear receptors, affecting transcription of genes involved in inflammation (downregulation of NF-κB and pro-inflammatory cytokines), cell-cycle regulation (with selective effects in rapidly-dividing cells including tumor cells), and metabolic regulation (insulin sensitivity, glucose handling, lipid metabolism). The RORα pathway is implicated in melatonin's anti-inflammatory and oncostatic effects and is not replicated by MT1/MT2-selective synthetic agonists — a potentially important distinction for the oncology and inflammatory-disease applications of melatonin but not of ramelteon.

Direct antioxidant and mitochondrial-protective activity is a third major mechanism. Melatonin is one of the most broad-spectrum endogenous free-radical scavengers known, with activity against hydroxyl radicals, peroxyl radicals, singlet oxygen, peroxynitrite, and superoxide anions. Its antioxidant capacity is several-fold greater than vitamin E per mole in many assays. Mechanistically, the indole nitrogen and the 5-methoxy group combine to donate electrons to radical species; unlike many antioxidants (which become pro-oxidants after donating electrons), melatonin's oxidized metabolites — particularly AFMK (N1-acetyl-N2-formyl-5-methoxykynuramine) and AMK (N1-acetyl-5-methoxykynuramine) — are themselves antioxidants, producing a radical-scavenging cascade that continues beyond the first electron donation.

Melatonin concentrates particularly in mitochondria (via active transport and lipid-partition equilibrium) where it protects mitochondrial membranes from oxidative damage, stabilizes the electron transport chain, preserves ATP synthesis under stress, and reduces mitochondrial permeability transition (a key event in apoptotic and ischemic cell death). These mitochondrial effects explain melatonin's protective role in ischemia-reperfusion injury (cardiac, cerebral), neurodegeneration models (Parkinson, Alzheimer, Huntington), and selective oncostatic effects in cancer cells that depend on oxidative phosphorylation (the Warburg-reverse phenomenon in cancer metabolism). The mitochondrial concentration of endogenously synthesized or exogenously administered melatonin can reach substantially higher levels than plasma concentration, explaining some therapeutic effects at high doses that wouldn't be predicted from receptor-based mechanisms alone.

Calcium-calmodulin modulation and membrane effects constitute the fourth axis. Melatonin binds calmodulin and modulates calcium signaling in neurons, which contributes to both its sedative-hypnotic effects and its actions on neuronal excitability. Melatonin also integrates into lipid bilayers, altering membrane fluidity and protecting against oxidative membrane damage — a contributor to its neuroprotective profile in ischemia and neurodegeneration.

Pharmacokinetics: Oral melatonin has low and variable bioavailability (typically 15-35%), with substantial first-pass hepatic metabolism via CYP1A2 (primary) and CYP2C19 (secondary). Peak plasma concentration occurs 45-90 minutes after oral administration, and elimination half-life is short (approximately 35-50 minutes for immediate-release formulations). Extended-release formulations (Circadin, various OTC delayed-release) provide more physiological overnight exposure. CYP1A2 inhibitors dramatically elevate melatonin exposure: fluvoxamine (a potent CYP1A2 inhibitor) can increase melatonin AUC 17-23 fold, a clinically significant interaction. Smoking (which induces CYP1A2) modestly reduces melatonin exposure. Oral contraceptives, caffeine, and verapamil have modest effects on melatonin metabolism. Most melatonin is excreted as 6-sulfatoxymelatonin, which can be measured in 24-hour urine as an indicator of total endogenous melatonin production.

The physiological dose range of endogenous melatonin — achieving plasma concentrations similar to nighttime endogenous peak (60-70 pg/mL) — requires approximately 0.1-0.3mg oral dose in healthy young adults. Doses of 1-3mg produce plasma levels 3-5× physiological night peak, doses of 5-10mg produce levels 10-25× physiological, and doses of 10-20mg (common in OTC products) produce clearly supraphysiological exposures. The supraphysiological exposure window likely accounts for much of the morning grogginess, vivid-dream, and paradoxical-insomnia reports at higher doses. For purely chronobiotic (phase-shifting) effects, 0.3mg is sufficient; higher doses do not produce proportionally greater phase shifts and may paradoxically reduce phase-shifting efficacy through receptor desensitization.

Melatonin (chemical name N-acetyl-5-methoxytryptamine) is an endogenous neurohormone synthesized primarily by the pineal gland and, in smaller quantities, by the retina, gut, skin, bone marrow, lymphocytes, and mitochondria across most tissues. It is the body's principal circadian signaling molecule, translating environmental light/dark information into an internal chemical representation of biological night. Endogenous melatonin secretion follows a precise circadian rhythm: plasma concentrations are low during the day (typically <10 pg/mL), begin rising 1-3 hours before habitual sleep onset (the "dim light melatonin onset" or DLMO), peak between 2am and 4am at 60-70 pg/mL in healthy young adults, and decline to baseline by morning. This nightly pulse coordinates sleep initiation, thermoregulation, circadian phase, seasonal reproductive physiology in some species, antioxidant defense (particularly in mitochondria), and immune-system oscillations.

Melatonin was discovered and named by Aaron Lerner at Yale in 1958 during research on pineal factors affecting amphibian skin coloration. Its role as the principal mediator of vertebrate photoperiodism was established through the 1960s-70s, its receptor targets (MT1 and MT2, both G-protein-coupled receptors) were cloned in the 1990s, and its broader pleiotropic functions beyond circadian signaling — including powerful free-radical scavenging, mitochondrial protection, oncostatic activity in hormone-sensitive tumors, immunomodulation, and metabolic effects on glucose and blood pressure — have emerged as active research areas over the past three decades. In 2026, melatonin occupies a unique regulatory position globally: in the United States, it is classified as a dietary supplement and available without prescription at virtually any pharmacy, grocery store, or online retailer, in doses ranging from micrograms to 20mg. In Europe, the UK, Australia, and several Asian countries, melatonin is a prescription-only medication (brand names Circadin for adult primary insomnia, Slenyto for pediatric insomnia in autism spectrum disorder), reflecting those regulators' assessment that it is a hormone rather than a nutritional supplement.

In popular supplement culture, melatonin is often framed simply as a "sleep aid," but this framing substantially understates both its mechanism and its appropriate use cases. Melatonin is not primarily hypnotic in the pharmacological sense of sedatives like benzodiazepines, Z-drugs, or antihistamines — those compounds produce sleep by direct suppression of arousal systems. Melatonin instead acts as a chronobiotic, shifting the timing of the circadian pacemaker in the suprachiasmatic nucleus (SCN) and creating a biological "signal for night" that allows downstream sleep-promoting processes to operate. The implications are significant: melatonin is most effective when timing is precisely aligned with the user's target sleep phase rather than maximal dose, and it is most useful for circadian rhythm disorders (delayed sleep phase syndrome, jet lag, shift work, non-24-hour sleep-wake disorder in blind individuals, free-running disorder, REM sleep behavior disorder) rather than for primary insomnia in the pharmacological sense.

The clinical evidence base is strongest and most consistent for: (1) jet lag — where multiple meta-analyses including Herxheimer & Petrie 2001 Cochrane reviewdocument strong efficacy when taken at bedtime in the destination time zone for eastward travel across >5 time zones; (2) delayed sleep phase syndrome (DSPS), where low-dose evening melatonin taken 5-7 hours before habitual sleep onset produces phase advances; (3) pediatric sleep disorders in children with autism spectrum disorder and ADHD, where multiple randomized trials and meta-analyses (Rossignol & Frye 2011, PMID: 21518346) document clear benefit for sleep onset latency and total sleep time; (4) REM sleep behavior disorder (RBD), where melatonin 3-12mg at bedtime reduces dream enactment episodes and is often preferred to clonazepam for older adults (Boeve et al. 2003); (5) non-24-hour sleep-wake disorder in totally blind individuals, where entrainment to the 24-hour day is achieved by carefully-timed evening melatonin.

Evidence is moderately positive for primary insomnia sleep onset latency (meta-analyses including Ferracioli-Oda et al. 2013 in PLOS One, PMID: 23691095, show modest but statistically significant reductions in sleep onset latency of approximately 7-12 minutes on average, smaller than typical hypnotic effects but clinically meaningful for some individuals), shift-work adaptation, migraine prophylaxis (Gonçalves et al. 2016, PMID: 27165014, showed melatonin 3mg nightly non-inferior to amitriptyline 25mg for chronic migraine prevention), and as an adjunct in blood-pressure management. Evidence is preliminary but compelling for melatonin as an adjunct in selected oncology protocols (particularly hormone-sensitive breast, prostate, and gastrointestinal cancers where meta-analyses including Seely et al. 2012, suggest survival benefit when combined with standard therapy), for COVID-19 adjunctive care, and for pre-operative anxiolysis in pediatric surgery. Evidence is mixed or unclear for general anxiolysis, weight management, and fertility support — claims that circulate in supplement culture but lack strong clinical backing.

A distinguishing feature of melatonin compared to other sleep aids is its extraordinarily wide safety margin and minimal abuse potential. Unlike benzodiazepines or Z-drugs, melatonin produces no physiological tolerance or dependence, does not suppress REM sleep architecture, does not impair next-day cognitive performance at appropriate doses, and has been used clinically in doses up to 300mg/day for certain oncology indications without serious acute toxicity. However, the practical sleep-supplement literature has been progressively revealing that most over-the-counter melatonin doses (3mg, 5mg, 10mg) are 10-30× higher than needed for sleep effects and that higher doses paradoxically produce worse outcomes via morning grogginess, nightmare frequency, and receptor desensitization. The current physiological-replacement approach — 0.3-1mg taken 30-60 minutes before desired sleep onset — is more effective than megadoses for most primary insomnia and sleep-timing applications.

See also Ashwagandha, L-theanine, Magnesium, Glycine, 5-HTP, and Vitamin D for adjacent sleep and circadian support compounds. This overview is educational only and is not medical advice — melatonin is a hormone with metabolic, reproductive, immune, and chronobiotic effects, and extended high-dose use warrants physician consultation.

IUPAC Name

Not yet available

CAS Number

Not yet available

Molecular Formula

Not yet available

Molecular Mass

Not yet available

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Get Melatonin Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Side-by-Side Comparisons

Related Articles

Data Completeness

Research Credibility